Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study

Lancet

Volumn 370, Issue 9601, 2007, Pages 1757-1763

  Vesikari, T ^a   Karvonen, A ^a   Prymula, R ^b   Schuster, V ^c   Tejedor, JC ^d   Cohen, R ^e   Meurice, F ^f   Han, HH ^f   Damaso, S ^f   Bouckenooghe, A ^f  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d HOSPITAL DE MÓSTOLES   (Spain)

^e Medical Facility   (France)

^f GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; PLACEBO; RIX 4414; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CHILDHOOD; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; FECES; FEMALE; FOLLOW UP; GASTROENTERITIS; HOSPITAL ADMISSION; HUMAN; INFANT; INTUSSUSCEPTION; LIFE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROTAVIRUS; ROTAVIRUS GASTROENTERITIS; STATISTICAL SIGNIFICANCE; VACCINATION; VIRUS TYPING;

EID: 36248995945     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61744-9     Document Type: Article

References (28)

1. Parashar U., Gibson C., Bresee J., and Glass R. Rotavirus and severe childhood diarrhoea. Emerg Infect Dis 12 (2006) 304-306
2. Soriano-Gabarro M., Mrukowicz J., Vesikari T., and Verstraten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 25 (2006) S7-S11
3. Bernstein D., Smith V., Sherwood J., et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 16 (1998) 381-387
4. Bernstein D., Sack D., Rothstein E., et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet 354 (1999) 287-290
5. Bernstein D., Sack D., Reisinger K., Rothstein E., and Ward R. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. J Infect Dis 186 (2002) 1487-1489
6. Vesikari T., Karvonen A., Korhonen T., et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 22 (2004) 2836-2842
7. Vesikari T., Karvonen A., Puustinen L., et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 23 (2004) 937-943
8. Salinas B., Perez-Schael I., Linhares A., et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine RIX4414: a randomised, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 24 (2005) 807-816
9. Dennehy P., Brady R., Scott H., et al. Comparative evaluation of safety and immunogenicity of two doses of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J 24 (2005) 481-488
10. Ruíz-Palacios G., Pérez-Schael I., Velázquez F., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354 (2006) 11-22
11. Ruuska T., and Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for severity of diarrheal episodes. Scand J Infect Dis 22 (1990) 259-267
12. Bresee J., Fang Z.-Y., Wang B., et al. First report from the Asian Rotavirus Surveillance Network. Emerg Infect Dis 10 (2004) 988-995
13. Griffin D., Kirkwood C., Parashar U., et al. Surveillance of rotavirus strains in the United States: identification of unusual strains. J Clin Microbiol 38 (2000) 2784-2787
14. Hsu V., Staat M., Roberts N., et al. Use of active surveillance to validate international classification of diseases code estimates of rotavirus hospitalisations in children. Pediatrics 115 (2005) 78-82
15. van Doorn LJ, Kleter B, Hoefnagel E, et al. Detection and genotyping of human rotavirus VP4 and VP7 genes in stool samples by reverse transcriptase PCR and reverse hybridization (abstr W6.5). Presented at 9th dsRNA Virus Meeting; Cape Town, South Africa; 21-26 Oct, 2006.
16. Ward R., Bernstein D., Shukla R., et al. Effect of antibody to rotavirus on protection of adults challenged with human rotavirus. J Infect Dis 159 (1989) 79-88
17. Tang M., and Ng H. Comment on: confidence limits for the ratio of two rates based on likelihood scores-non-iterative method. Stat Med 23 (2004) 685-691
18. Vesikari T., Ruuska T., Green K., Flores J., and Kapikian A. Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity. Pediatr Infect Dis J 11 (1992) 535-542
19. Vesikari T., Matson D., Dennehy P., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354 (2006) 23-33
20. Joensuu J., Koskenniemi E., Pang X., and Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 350 (1997) 1205-1209
21. Santos N., and Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 15 (2005) 29-56
22. Desselberger U., Wolleswinkel-van den Bosch J., Mrukowicz J., Rodrigo C., Giaquinto C., and Vesikari T. Rotavirus types in Europe and their significance for vaccination. Pediatr Infect Dis J 25 suppl 1 (2006) S30-S41
23. Van Damme P., Giaquinto C., Maxwell M., Todd P., and Van der Wielen M. Distribution of rotavirus genotypes in Europe, 2004-2005: the REVEAL study. J Infect Dis 195 (2007) S17-S25
24. Offit P. Rotaviruses: immunological determinants of protection against infection and disease. Adv Virus Res 44 (1994) 161-202
25. Ward R., McNeal M., Sander D., Greenberg H., and Bernstein D. Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children. J Virol 67 (1993) 464-468
26. Midthuin K., and Kapikian A. Rotavirus vaccines: an overview. Clin Microbiol Rev 9 (1996) 423-434
27. Velázquez FR, Abate H, Bouckenooghe A, et al. RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life (presentation G-617). Presented at the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Francisco, CA, USA; Sept 27-30, 2006.
28. De Vos B, Gillard P, Cheuvart B, Debrus S, Han HH, Bouckenooghe A. RIX4414 vaccine efficacy against rotavirus gastroenteritis due to G2P[4] strain (presentation G-618). Presented at the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Francisco, CA, USA; Sept 27-30, 2006.